06 sep: British American Tobacco Buys Back 220,000 Shares for Treasury/3,..
06 sep: 3rd UPDATE: ECB Reveals Bond Plan, Weidmann Left Isolated
06-09-2012 18:45:00

Weak August Sales, Tricare Decision Weigh on Walgreen

Relateret indhold
Relateret debat
08 jan - 
Express Scripts - ser meget spændende ud, og har givet ..

--Shares fall despite broader market rally as investors digest disappointing sales news and Tricare's network decision

--Tricare health plan won't let its beneficiaries who get drug coverage through Express Scripts resume getting prescriptions filled at Walgreen

--Walgreen had previously indicated Tricare represented about 15 million prescriptions in 2011

Shares of Walgreen Co. (WAG) are under pressure Thursday as the broader market rallies, with investors digesting news of weak sales in August and a decision by the U.S. Department of Defense's Tricare health plan to continue to exclude the pharmacy chain from its provider network.

Earlier Thursday, Walgreen said the company's same-store sales fell a bigger-than-expected 8.2% during August, as the pharmacy giant continued to suffer from generic-drug introductions and its dispute with Express Scripts Holding Co. (ESRX). Analysts surveyed by Thomson Reuters expected a decline of 7.3%.

Though August's same-store sales and total sales for the fiscal fourth quarter were disappointing, analysts and investors seemed to focus more on Tricare's announcement Wednesday evening, when it said it wouldn't let its nearly 10 million beneficiaries who get drug coverage through Express Scripts resume getting prescriptions filled at Walgreen outlets.

Walgreen had previously indicated Tricare represented about 15 million prescriptions in 2011, making up about 17% of the 88 million prescriptions filled at Walgreen pharmacies by Express Scripts members last year.

The decision is a setback for Walgreen as the drugstore chain tries to gain customers it lost starting Jan. 1, when it broke ties with Express Scripts. Walgreen and Express Scripts recently mended fences, but entities that hire Express Scripts to manage pharmacy benefits will have to specifically add Walgreen drugstores to their network before members can get prescriptions covered there.

Tricare's decision highlights the heightened interest among employers and health plans to opt for so-called "narrow networks," as clients look for savings by aiming to balance between drugstore options and prices for health-plan sponsors.

Though Walgreen has contended that clients aren't interested in narrow networks, J.P. Morgan analyst Lisa Gill in a research note said the current selling season for pharmacy-benefit managers showed more interest in the savings narrow networks can drive.

"We believe the Tricare decision is an incremental positive for CVS, as it should help lead to higher long-term prescription-retention rates," Ms. Gill said.

Shares of CVS Caremark Corp. (CVS) were up 1.9% to $46.40, better than the broader market's rally, while Walgreen's stock fell 2.5% to $34.98.

Jefferies analyst Brian Tanquilut said that while some Express Scripts clients, such as managed-care provider WellPoint Inc. (WLP), have adopted a broader pharmacy network that includes Walgreen beginning Sept. 15, Tricare's move bolsters Express Scripts's push for narrower networks. By restricting access to more-expensive retail pharmacies, Mr. Tanquilut said clients could reduce pharmacy costs while the company can generate better margins.

In August, Walgreen saw its sales fall 4.5% from the year-ago month to $5.85 billion.

Total comparable-store front-end sales decreased 0.6%, while prescriptions filled at comparable stores decreased 6.8% in August. Walgreen said the negative impact on comparable-store prescriptions filled due to not being part of the Express Scripts pharmacy network was 10.7 percentage points in August. Prescriptions processed by Express Scripts comprised about 13% of Walgreen prescriptions in August 2011.

Walgreen said the effect of generic-drug introductions in the last 12 months hurt total comparable sales by 5.1 percentage points. The industry's same-store sales have been hurt by rising demand for new generic drugs hitting the market, as they carry lower prices than branded products.

Total sales for the fiscal fourth quarter fell 4.9% to $17.08 billion, below analysts' expectations of $17.21 billion. Comparable-store sales for the fourth quarter decreased 8.7%, while front-end comparable-store sales for the quarter decreased 1.3%. Prescriptions filled at comparable stores decreased 8% in the fourth quarter, and comparable-pharmacy sales decreased 13%.

--Jon Kamp and Saabira Chaudhuri contributed to this article.

Write to John Kell at john.kell@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

(END) Dow Jones Newswires

September 06, 2012 12:45 ET (16:45 GMT)

Copyright (c) 2012 Dow Jones & Company, Inc.

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
Ingen indlæg

Fondsbørsmeddelelser

Roblon Q1: Bundlinjen næsten fordoblet

26-02-2015 16:36:53
Roblon kan notere sig en lille fremgang på toplinjen og et næsten fordoblet overskud i første kvartal af det forskudte regnskabsår sammenlignet med same periode..

Fakta: Kapløbet om det amerikanske marked for basal insulin

26-02-2015 13:49:38
Der er store milliardindtægter på spil for Novo Nordisk og selskabets konkurrenter på det amerikanske marked for langtidsvirkende insulin. Derfor kæmper selskab..

Aktier/åbning: Rekordkursen fortsætter - nu med William i front

26-02-2015 09:15:06
Rekordernes tid er tilsyneladende endnu ikke overstået. Det danske aktiemarked holder rekordkursen fra åbningen torsdag, efter at C20 Cap-indekset onsdag satte ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Vestas: Goldwind slår analytikernes forventninger i årsregnskab
2
Aktier/tendens: Novo, WDH og Mærsk kan diktere retningen
3
Vestas-konkurrent fordobler overskud og opjusterer - NY
4
Nationalbanken fastslår: Vi har rigeligt penge i kassen
5
Novo: Ærkerival får grønt lys til nyt insulin - NY

Relaterede aktiekurser

Køb- og salgsanbefalinger

  • Trend
  • Pengemaskinen

Relaterede selskaber
Få adgang til information og anbefalinger af relaterede selskaber med PLUS pakken.

Du får adgang til 7 værdifulde investorværktøjer til investering.

Klik her og læs mere om PLUS pakken.

Copyright Euroinvestor A/S 2015  Disclaimer Privatlivspolitik
Aktieinformation leveres af Interactive Data.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
27. februar 2015 01:28:46
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20150225.2 - EUROWEB4 - 2015-02-27 01:28:46 - 2015-02-27 01:28:46 - 1 - Website: OKAY

Når du besøger Euroinvestor.dk accepterer du, at der anvendes cookies, som vi og vores samarbejdspartnere benytter til funktionalitet, statistik og markedsføring. Læs mere om cookies på Euroinvestor.dk her

x